Osteopathic Manual Treatment and Ultrasound Therapy for Chronic Low Back Pain: A Randomized Controlled Trial

John C. Licciardone, DO, MS, MBA[1,2]

Dennis E. Minotti, DO[1]

Robert J. Gatchel, PhD[1,3]

Cathleen M. Kearns, BA[1]

Karan P. Singh, PhD[1,4]

[1]The Osteopathic Research Center, University of North Texas Health Science Center, Fort Worth, Texas

[2]Department of Medical Education, Texas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, Texas

[3]Department of Psychology, College of Science, University of Texas at Arlington, Arlington, Texas

[4]Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama

MORE ONLINE
www.annfammed.org

Conflicts of interest: authors report none.

CORRESPONDING AUTHOR

John C. Licciardone, DO, MS, MBA
The Osteopathic Research Center
3500 Camp Bowie Blvd
Fort Worth, TX 76107
john.licciardone@unthsc.edu

ABSTRACT

PURPOSE We studied the efficacy of osteopathic manual treatment (OMT) and ultrasound therapy (UST) for chronic low back pain.

METHODS A randomized, double-blind, sham-controlled, 2×2 factorial design was used to study OMT and UST for short-term relief of nonspecific chronic low back pain. The 455 patients were randomized to OMT (n = 230) or sham OMT (n = 225) main effects groups, and to UST (n = 233) or sham UST (n = 222) main effects groups. Six treatment sessions were provided over 8 weeks. Intention-to-treat analysis was performed to measure moderate and substantial improvements in low back pain at week 12 (30% or greater and 50% or greater pain reductions from baseline, respectively). Five secondary outcomes, safety, and treatment adherence were also assessed.

RESULTS There was no statistical interaction between OMT and UST. Patients receiving OMT were more likely than patients receiving sham OMT to achieve moderate (response ratio [RR] = 1.38; 95% CI, 1.16-1.64; *P* <.001) and substantial (RR = 1.41, 95% CI, 1.13-1.76; *P* = .002) improvements in low back pain at week 12. These improvements met the Cochrane Back Review Group criterion for a medium effect size. Back-specific functioning, general health, work disability specific to low back pain, safety outcomes, and treatment adherence did not differ between patients receiving OMT and sham OMT. Nevertheless, patients in the OMT group were more likely to be very satisfied with their back care throughout the study (*P* <.001). Patients receiving OMT used prescription drugs for low back pain less frequently during the 12 weeks than did patients in the sham OMT group (use ratio = 0.66, 95% CI, 0.43-1.00; *P* = .048). Ultrasound therapy was not efficacious.

CONCLUSIONS The OMT regimen met or exceeded the Cochrane Back Review Group criterion for a medium effect size in relieving chronic low back pain. It was safe, parsimonious, and well accepted by patients.

Ann Fam Med 2013;11:122-129. doi:10.1370/afm.1468.

INTRODUCTION

Low back pain is primarily responsible for more than 20 million ambulatory medical care visits[1] and $100 billion in costs[2] annually in the United States. When low back pain persists for 3 months, it is considered chronic and may cause progressive physical and psychological effects.[3] Although practice guidelines recommend considering spinal manipulation for chronic or persistent low back pain,[4,5] a Cochrane Collaboration review concluded that spinal manipulation is not more effective than sham interventions for short-term relief of chronic low back pain.[6] The effectiveness of spinal manipulation remains controversial among family physicians.[7] Osteopathic manual treatment (OMT) is delivered by osteopathic physicians in the United States, and by osteopaths in many other nations. No trial of

OMT has conclusively found efficacy in relieving low back pain[8-13] or achieved a status of low risk of bias.[6] High-quality trials of ultrasound therapy (UST) are also needed to assess its efficacy compared with sham procedures.[14] The OSTEOPAThic Health outcomes In Chronic low back pain (OSTEOPATHIC) Trial aims to fill these voids by studying OMT and UST for short-term relief of nonspecific chronic low back pain.

METHODS

Design Overview

The OSTEOPATHIC Trial used a randomized, double-blind, sham-controlled, 2×2 factorial design to study OMT and UST.[15] The study was designed to compare main effects (OMT vs sham OMT, and UST vs sham UST) (Figure 1). It was approved by the Institutional Review Board at the University of North Texas Health Science Center.

Setting and Patients

We recruited patients in Dallas-Fort Worth, Texas, from August 2006 to September 2010 through newspaper advertisements, community agencies, and medical clinics, including those affiliated with the group practice of the University of North Texas Health Science Center, but excluding clinics that provided OMT specialty services. Adult (aged 21 to 69 years) nonpregnant individuals with low back pain for at least 3 months were telephonically screened for the following exclusion criteria: red flag conditions (cancer, spinal osteomyelitis, spinal fracture, herniated disc, ankylosing spondylitis, or cauda equina syndrome); low back surgery in the past year; workers' compensation benefits in the past 3 months; ongoing litigation involving back problems; angina or congestive heart failure symptoms with minimal activity, history

of a stroke, or transient ischemic attack in the past year; implanted biomedical devices (such as cardiac pacemakers or artificial joints); active bleeding or infection in the lower back, or other conditions impeding protocol implementation; use of corticosteroids in the past month; or use of manual treatment (OMT or manual therapies delivered by chiropractors or physical therapists) or UST in the past 3 months or more than 3 times in the past year. Candidates whose screening was successful by telephone received a clinical screening to exclude those with a high probability of lumbar radiculopathy, a specific cause of low back pain and a relative contraindication to OMT. Clinical screening involved testing for ankle dorsiflexion weakness, great toe extensor weakness, impaired ankle reflexes, loss of light touch sensation in the medial, dorsal, and lateral aspects of the foot, ipsilateral straight leg raising, and crossed straight leg raising.[16]

Randomization, Allocation Concealment, and Blinding

Patients were allocated to OMT + UST, OMT + sham UST, sham OMT + UST, or sham OMT + sham UST at the central randomization site based on a computer program that generated pseudorandom numbers. Patients were secondarily allocated to type of physician (faculty physician, predoctoral fellow, or resident) using stratified randomization. Assignments were then conveyed directly to the physicians using numbered, opaque sealed envelopes, which were subsequently placed in secured, segregated treatment files. Patients and outcome assessors remained unaware of group assignments at randomization.

Interventions

Treatments were scheduled at weeks 0, 1, 2, 4, 6, and 8 using 15 different physicians. We maintained the same physician at recurring treatment sessions for a given patient unless there was a scheduling conflict. Patients could self-initiate low back pain co-treatments, such as nonprescription drugs and complementary and alternative medicine therapies. Patients could also independently receive low back pain usual care (any co-treatments except OMT, other manual therapies, or UST) at any time from physicians not associated with the study. Co-treatments were documented at 4-week intervals throughout the study.

Active and Sham Osteopathic Manual Treatment

The OMT techniques were delivered after a standard diagnostic evaluation[17] at each treatment session. The lumbosacral, iliac, and pubic regions were targeted using high-velocity, low-amplitude thrusts; moderate-velocity, moderate-amplitude thrusts; soft tissue stretching, kneading, and pressure; myofascial stretch-

Figure 1. Allocation of patients to osteopathic manual treatment and ultrasound therapy interventions using a 2×2 factorial design.

Osteopathic Manual Treatment (OMT)

	Active	Sham	
Ultrasound Therapy (UST) — Active	OMT + UST	Sham OMT + UST	UST Main Effects
Ultrasound Therapy (UST) — Sham	OMT + Sham UST	Sham OMT + Sham UST	Sham UST Main Effects
	OMT Main Effects	Sham OMT Main Effects	

ing and release; positional treatment of myofascial tender points; and patient's isometric muscle activation against the physician's unyielding and equal counterforce. Time permitting, optional techniques[18] could be used if the physician judged 1 or more of the 6 designated techniques to be contraindicated or ineffective.

Sham OMT was aimed at the same anatomical regions as active OMT. Sham OMT involved hand contact, active and passive range of motion, and techniques that simulated OMT but that used such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished physician force. Similar methods achieved a robust placebo response[13] when compared with other placebo treatments for pain.[19] Our methods have been adopted by others to deliver sham manipulation.[20]

Active and Sham Ultrasound Therapy

The UST intervention was delivered after the OMT intervention, using the Sonicator 730 (Mettler Electronics Corp), with a 10 cm^2 applicator at an intensity of 1.2 W/cm^2 and frequency of 1 MHz in continuous mode. Conductivity gel was used to enhance absorption and produce deep muscle thermal effects.[21] About 150 to 200 cm^2 of the lower back were treated. Sham UST was delivered in the same manner at a subtherapeutic intensity (0.1 W/cm^2).[22]

Treatment Fidelity and Adherence

Training for physicians delivering the treatment was conducted at regular intervals using strategies to enhance protocol implementation and treatment fidelity, including provision of sham treatments.[23] A standard form was used at each treatment session to ensure consistency in delivery of active or sham OMT for 15 minutes, and of active or sham UST for 10 minutes. Both OMT and UST interventions were delivered by the same physician during a treatment session. Treatment adherence and reported pain levels were used as surrogate measures of patient blinding.

Outcomes

Primary Low Back Pain Outcomes

The current level of low back pain was measured before each treatment and at week 12 using a 100-mm visual analog scale. Primary outcomes were based on the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) consensus statement recommendations for moderate (30% or greater pain reduction) and substantial (50% or greater pain reduction) improvement.[24] Such reductions are highly sensitive and specific in predicting global impression of change in chronic pain patients[25] and provide tangible evidence for clinical applications.[26]

Secondary Outcomes

Patient-based secondary outcomes[27] were measured at baseline and at weeks 4, 8, and 12, using the Roland-Morris Disability Questionnaire (RMDQ),[28] Medical Outcomes Study Short Form-36 Health Survey general health scale (SF-36 GH),[29] number of lost work days in the past 4 weeks because of low back pain, and satisfaction with back care on a 5-point Likert scale. We measured 8 low back pain co-treatments reported by patients as being self-initiated or received from independent, community-based clinicians.

Safety Monitoring

Blinded research personnel assessed patients for contraindications to continued participation or adverse events at each encounter. An independent safety officer reviewed all reported contraindications and adverse events to identify any serious adverse events, defined as deaths, life-threatening situations, hospitalizations, severe or permanent disability, or other important medical events. The safety officer also assessed causality of serious adverse events in relation to study interventions.

Sample Size

The planned sample size of 488 was designed for a statistical power of 82% or greater in testing OMT vs sham OMT main effects (standardized mean difference of 0.264 for OMT vs control treatments,[30] corresponding to a between-group difference of 6.6 mm on a 100-mm visual analog scale, with a standard deviation of 25 mm[31]). In September 2010, under supervision of the Data and Safety Monitoring Board, an unplanned interim analysis was performed using visual analog scale change scores over 12 weeks that were measured through the provisional study end date of June 2010. This analysis was undertaken to determine whether the study could be terminated with 455 (93%) of the planned number of patients having enrolled in the study. Alternatively, additional sources of funding would have been required for further recruitment and study completion. The results of this analysis indicated that the change scores for OMT patients were significantly better than for sham OMT patients ($P = .003$). This finding crossed the O'Brien-Fleming stopping boundary ($P = .005$).[32] Consequently, study recruitment was terminated.

Statistical Analysis

Low Back Pain Outcomes

We observed a bimodal distribution of visual analog scale change scores and corresponding marginal test for normality ($P = .08$). Consequently, we used the median and interquartile range (IQR) as descriptive measures, and the Mann-Whitney test and contingency

table methods for analysis of low back pain outcomes. Responder analysis was used to assess treatment effects at week 12, with a focus on moderate and substantial improvements in low back pain.[24] Response ratios (RRs) and 95% confidence intervals for active vs sham treatments were used to interpret treatment effects. Significant results were considered clinically relevant if they met the Cochrane Back Review Group criteria for medium (1.25 ≤RR ≤2) or large (RR >2) effect sizes.[33]

To test for statistical interaction between OMT and UST, we performed repeated measures analysis of variance on the ranked visual analog scale pain scores for each protocol visit, with the ranked baseline pain score as a covariate. Rothman's T statistic[34] was used to test for statistical interaction between OMT and UST based on moderate and substantial improvements in low back pain with each intervention. Any significant departure from $T = 0$ was indicative of interaction.

Secondary Outcomes

The distributions of secondary outcome measures also mandated use of nonparametric methods. The Mann-Whitney test was used to analyze RMDQ and SF-36 GH scores at weeks 4, 8, and 12. We dichotomized disability specific to low back pain (0 vs ≥1 lost work days in the past 4 weeks), satisfaction with back care (very satisfied vs any other response), and use of low back pain co-treatments (no use vs any use during the study).

Other Statistical Methods

Patient flow, treatment adherence, and safety were assessed by contingency table methods. Hypothesis testing was by intention to treat, with a 2-sided α = .05. Missing data were generally imputed using the last observation carried forward. For the multi-item RMDQ and SF-36 GH outcomes, however, we preferentially used responses acquired during a given encounter whenever possible to impute missing data for that encounter.[29] Sensitivity analysis was conducted to assess the impact of missing data and robustness of our imputation methods. First, we conducted per-protocol analysis using only the 362 patients with complete data. Second, we conducted an alternate analysis in which any patient with 1 or more missed treatments was considered to be a nonresponder. We did not specify a priori subgroup analyses because of concerns about statistical power and confounding in such analyses.[35] Statistical analyses were performed with SPSS 17.0.3 (SPSS Inc), using Epi Info 6.04d (Centers for Disease Control and Prevention) for low back pain treatment effects.

RESULTS

Patient Flow and Characteristics

Baseline patient characteristics were comparable across main effects groups (Table 1). The patient flow diagram displays similar allocation to physicians, follow-up, and

Table 1. Baseline Patient Characteristics by Main Effects Group

Characteristic	OMT vs Sham OMT		UST vs Sham UST		Total (N = 455)
	OMT (n = 230)	Sham OMT (n = 225)	UST (n = 233)	Sham UST (n = 222)	
Age, median (IQR), y	41 (29-51)	40 (29-50)	38 (29-50)	43 (30-51)	41 (29-51)
Women, No. (%)	144 (63)	140 (62)	134 (58)	150 (68)	284 (62)
Completed college education, No. (%)	107 (47)	93 (41)	102 (44)	98 (44)	200 (44)
Employed full-time, No. (%)	110 (48)	105 (47)	114 (49)	101 (45)	215 (47)
Medically uninsured, No. (%)	86 (37)	77 (34)	79 (34)	84 (38)	163 (36)
Current smoker, No. (%)	61 (27)	58 (26)	61 (26)	58 (26)	119 (26)
Comorbid conditions, No. (%)					
Hypertension	42 (18)	29 (13)	34 (15)	37 (17)	71 (16)
Diabetes mellitus	19 (8)	15 (7)	17 (7)	17 (8)	34 (7)
Osteoarthritis	17 (7)	16 (7)	15 (6)	18 (8)	33 (7)
Depression	44 (19)	46 (20)	41 (18)	49 (22)	90 (20)
Duration of chronic LBP >1 y, No. (%)	118 (51)	110 (49)	119 (51)	109 (49)	228 (50)
Previously hospitalized for LBP, No. (%)	13 (6)	8 (4)	9 (4)	12 (5)	21 (5)
Previously had surgery for LBP, No. (%)	5 (2)	5 (2)	3 (1)	7 (3)	10 (2)
VAS score for LBP (mm) median (IQR)[a]	44 (25-61)	45 (28-60)	44 (29-60)	44 (23 to 61)	44 (26-60)
Roland-Morris disability score, median (IQR)[b]	5 (3-9)	5 (3-10)	5 (3-10)	5 (3-9)	5 (3-9)
SF-36 general health score, median (IQR)[c]	67 (57-82)	72 (52-85)	72 (56-85)	67 (52-82)	72 (52-82)
Used drugs for LBP during past 4 wk, No. (%)					
Nonprescription	115 (50)	107 (48)	119 (51)	103 (46)	222 (49)
Prescription	27 (12)	32 (14)	36 (15)	23 (10)	59 (13)

IQR = interquartile range; LBP = low back pain; OMT = osteopathic manual treatment; SF-36 = Medical Outcomes Study Short Form-36 Health Survey; UST = ultrasound therapy; VAS = visual analog scale.

[a] VAS (0-100 mm) used to measure LBP, with higher scores indicating more pain.

[b] Roland-Morris Disability Questionnaire (0-24 points) used to measure back-specific functioning, with higher scores indicating greater disability.

[c] SF-36 general health scale (0-100 points) used to measure generic health, with higher scores indicating better health.

treatment adherence among main effects groups (Supplemental Figure 1, available at http://annfammed.org/content/11/2/122/suppl/DC1). A total of 397 (87%) patients attended the final encounter at week 12.

Low Back Pain Outcomes

The repeated measures analysis of variance failed to reject the hypothesis of no interaction between OMT and UST ($P = .34$). This analysis further showed significant reductions in pain scores on the visual analog scale over time with OMT compared with sham OMT ($P = .002$), but not with UST compared with sham UST ($P = .99$). Correspondingly, the change scores on the visual analog scale at 12 weeks for OMT patients (median = –18 mm, IQR = –31 to 0 mm) were significantly better than for sham OMT patients (median = –9 mm, IQR = –25 to 3 mm ($P = .002$). There was no statistical interaction between OMT and UST in assessing moderate ($T = -0.04$; 95% CI, –0.22 to 0.14; $P = .63$) or substantial ($T = -0.05$; 95% CI, –0.23 to 0.13; $P = .61$) improvements in low back pain.

Overall, 145 (63%) OMT patients vs 103 (46%) sham OMT patients reported moderate improvement at week 12 (RR = 1.38; 95% CI, 1.16-1.64; P

<.001). Similarly, 114 (50%) OMT patients vs 79 (35%) sham OMT patients reported substantial improvement (RR = 1.41; 95% CI, 1.13-1.76; $P = .002$). By contrast, moderate improvement was observed in 128 (55%) UST patients vs 120 (54%) sham UST patients (RR = 1.02; 95% CI, 0.86-1.20; $P = .85$). Substantial improvement was observed in 103 (44%) UST patients vs 90 (41%) sham UST patients (RR = 1.09; 95% CI, 0.88-1.35; $P = .43$). The OMT treatment effects in chronic low back pain were also clinically relevant because they met or exceeded the Cochrane Back Review Group criterion for a medium effect size in all analyses for moderate to substantial improvements, including the sensitivity analyses (Table 2). Ultrasound therapy was not efficacious in any of these analyses.

Secondary Outcomes

Neither OMT nor UST yielded significant improvements in RMDQ or SF-36 GH scores (Table 3). Sham UST patients were less likely than UST patients and OMT patients were less likely than sham OMT patients to report work disability because of low back pain at weeks 4 and 8, respectively. Neither of these groups sustained significant improvements at week 12, however. The OMT patients were more likely than sham OMT patients to report being very satisfied with their back care at all endpoints ($P < .001$). A total of 31 (13%) OMT patients vs 46 (20%) sham OMT patients reported using prescription drugs for low back pain during the study (use ratio = 0.66; 95% CI, 0.43-1.00; $P = .048$). The statistical significance of this finding persisted after simultaneously controlling for all other co-treatments.

Safety Profiles

Only 1 patient developed a contraindication to continued participation that was adjudicated to be possibly related to OMT. This contraindication involved recurrent back spasticity following OMT. There were 27 (6%) patients with adverse events (Supplemental Figure 1). Nine (2%) patients had a serious adverse event, none of which was definitely or probably related to a study intervention. There were no significant differences between the main effects groups in the frequency of adverse events or serious adverse events.

Adequacy of Patient Blinding

All 6 treatments were attended by 191 (83%) OMT patients vs 191 (85%) sham

Table 2. Treatment Effects for Osteopathic Manual Treatment and Ultrasound Therapy in Chronic Low Back Pain

LBP Reduction Threshold[a]	OMT RR (95% CI)	UST RR (95% CI)
Intention-to-treat analysis (N = 455)		
≥30%	1.38 (1.16-1.64)	1.02 (0.86-1.20)
≥50%	1.41 (1.13-1.76)	1.09 (0.88-1.35)
≥20 mm	1.47 (1.17-1.86)	1.01 (0.80-1.26)
≥40 mm	1.96 (1.18-3.24)	1.09 (0.68-1.75)
Per-protocol analysis (n = 362)		
≥30%	1.42 (1.19-1.70)	1.03 (0.87-1.23)
≥50%	1.48 (1.18-1.86)	1.11 (0.89-1.38)
≥20 mm	1.44 (1.13-1.85)	1.05 (0.83-1.34)
≥40 mm	2.08 (1.21-3.58)	1.01 (0.61-1.67)
Patients with missed treatments considered nonresponders (N = 455)		
≥30%	1.38 (1.13-1.69)	0.97 (0.80-1.18)
≥50%	1.43 (1.12-1.83)	1.05 (0.82-1.33)
≥20 mm	1.40 (1.07-1.82)	0.99 (0.77-1.28)
≥40 mm	2.01 (1.16-3.49)	0.95 (0.57-1.59)

IMMPACT = Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials; LBP = low back pain; OMT = osteopathic manual treatment; RR = response ratio; UST = ultrasound therapy.

Note: Response ratios are for active vs sham treatments. RR >1 potentially indicates some level of response to active treatment. Using the Cochrane Back Review Group guidelines,[33] significant treatment effects are further classified as small, RR <1.25; medium, RR = 1.25 to ≤2.0; or large, RR >2. Thus, table entries for OMT effects were all in the medium to large range. There was no evidence of any treatment effect with UST, as no table entry achieved significance.

[a] IMMPACT benchmarks are ≥30% LBP reduction (moderate improvement) and ≥50% LBP reduction (substantial improvement).[24] Using absolute pain measures on a 100-mm visual analog scale, benchmarks are ≥20 mm LBP reduction (moderate improvement) and ≥40 mm LBP reduction (substantial improvement).

Table 3. Secondary Outcomes by Main Effects Group

Outcome	OMT vs Sham OMT			UST vs Sham UST		
	OMT (n = 230)	Sham OMT (n = 225)	P Value	UST (n = 233)	Sham UST (n = 222)	P Value
RMDQ score, median (IQR)[a]						
Week 4	4 (2-8)	5 (2-9)	.32	4 (2-9)	5 (2-8)	.99
Week 8	3 (1-7)	3 (2-8)	.14	3 (1-8)	4 (1-7)	.76
Week 12	2 (1-6)	3 (1-7)	.07	3 (1-7)	3 (1-7)	.93
SF-36 GH score, median (IQR)[b]						
Week 4	71 (55-82)	72 (52-86)	.39	72 (54-87)	72 (52-82)	.73
Week 8	72 (57-85)	72 (52-85)	.61	72 (54-85)	72 (57-85)	.53
Week 12	72 (52-87)	72 (57-87)	.87	72 (52-87)	74 (54-87)	.66
Lost 1 or more work days in past 4 weeks because of LBP, % (95% CI)[c]						
Week 4	10 (4-16)	14 (7-21)	.41	16 (9-23)	7 (2-12)	.04
Week 8	6 (2-11)	19 (12-27)	.005	17 (10-24)	8 (3-14)	.054
Week 12	11 (5-17)	8 (3-13)	.41	13 (6-19)	6 (1-11)	.11
Very satisfied with back care, % (95% CI)[d]						
Week 4	52 (46-59)	34 (28-41)	<.001	41 (35-48)	45 (38-52)	.44
Week 8	61 (54-67)	39 (33-46)	<.001	49 (43-56)	51 (44-58)	.77
Week 12	66 (60-73)	43 (36-50)	<.001	55 (48-61)	55 (48-62)	.99
LBP co-treatment during study, % (95% CI)[e]						
Exercise programs	19 (14-24)	20 (14-25)	.82	20 (15-25)	18 (13-24)	.73
Lumbar supports	1 (0-3)	1 (0-2)	>.99	1 (0-2)	1 (0-3)	.68
Nonprescription drugs	46 (39-52)	45 (39-52)	.95	46 (40-53)	45 (38-51)	.71
Prescription drugs	13 (9-18)	20 (15-26)	.048	16 (11-21)	18 (13-23)	.54
CAM therapies	15 (11-20)	17 (12-22)	.63	16 (12-21)	16 (11-21)	.87
Physical therapy	11 (7-15)	8 (4-11)	.17	9 (5-13)	10 (6-14)	.74
Hospitalization	0 (0-0)	0 (0-1)	.49	0 (0-1)	0 (0-0)	>.99
Surgery	0 (0-1)	0 (0-0)	>.99	0 (0-0)	0 (0-1)	.49

CAM = complementary and alternative medicine; IQR = interquartile range; LBP = low back pain; OMT = osteopathic manual treatment; RMDQ = Roland-Morris Disability Questionnaire; SF-36 GH = Medical Outcomes Study Short Form-36 Health Survey general health scale; UST = ultrasound therapy.

[a] Higher scores on the RMDQ represent greater disability. P values at each endpoint based on the Mann-Whitney test; N = 455 for all endpoints.

[b] Higher scores on the SF-36 GH represent better health. P values at each endpoint based on the Mann-Whitney test; N = 455 for all endpoints.

[c] Work disability analyses limited to the 215 patients employed full-time at baseline; n = 207, 211, and 211 at the successive endpoints.

[d] n = 416, 426, and 429 at the successive endpoints.

[e] N = 455 for all chronic LBP co-treatments.

OMT patients (adherence ratio = 0.98; 95% CI, 0.90-1.06; P = .59), and by 192 (82%) UST patients vs 190 (86%) sham UST patients (adherence ratio = 0.96; 95% CI, 0.89-1.04; P = .36). At week 12, sham OMT patients reported a median change score on the visual analog scale of –9 mm (IQR = –25 to 3 mm) vs –13 mm (IQR = –27 to 1 mm) reported by sham UST patients.

DISCUSSION

This study shows that OMT is efficacious for short-term pain relief when used to complement other co-treatments for chronic low back pain. Responder analysis confirmed that OMT met or exceeded the Cochrane Back Review Group criterion for a medium effect size for both moderate and substantial improvements in low back pain. Thus, low back pain reductions with OMT were statistically significant and clinically relevant. The less frequent use of prescription

drugs for low back pain reported by OMT patients further corroborates the clinical relevance of our low back pain outcomes. Notably, these drugs were prescribed by independent nonstudy physicians who were blinded or unaware that their patients were participating in our study. Moderate to substantial pain reductions, such as those observed with OMT, have been associated with decreased need for rescue medication.[26] Another trial reported decreased medication use with OMT, but without corresponding efficacy in relieving low back pain.[11] Our results may begin to explain why one-third of ambulatory, chronic problem visits for low back pain in the United States are provided by osteopathic physicians, and why they less frequently prescribe medications, such as nonsteroidal anti-inflammatory drugs, than allopathic physicians during such visits.[1]

There are concerns that chronic low back pain is often managed with costly and invasive treatments of questionable efficacy and safety.[36] Our results support

the efficacy and safety of OMT; however, they do not address its cost-effectiveness. Nevertheless, the OMT regimen of 6 treatments was within the guidelines developed in the United Kingdom by the National Institute for Health and Clinical Excellence, which recommend up to 9 spinal manipulation treatment sessions over 12 weeks.[5] Our results may be generalizable to other manual therapies because several OMT techniques in our protocol have been accepted for low back pain treatment by professional associations representing chiropractors and physiotherapists.[37] Biweekly maintenance treatments with spinal manipulation extend short-term low back pain reductions for 9 months.[20] A systematic review suggests that low back pain reductions with OMT may extend up to 1 year.[30] Thus, a larger trial is warranted to assess the efficacy and cost-effectiveness of OMT at long-term endpoints.

To our knowledge, this OMT trial is the largest ever conducted. Other strengths of our study include allocation concealment, similarity of baseline patient characteristics across treatment groups, blinding of outcome assessors, high levels of treatment adherence and outcomes reporting, and intention-to-treat analysis. Our analysis and interpretation of the primary outcomes was consistent with IMMPACT recommendations.[24,38] We also collected data on concurrent low back pain co-treatments to pragmatically assess the effectiveness of OMT as it is provided in real-life settings (ie, as a complement, rather than an alternative, to self-care and usual care for low back pain).

There were limitations of our study. Comorbid conditions, work disability, and low back pain co-treatments were self-reported by patients, but were not verified through medical or employment records. Also, missing data had to be imputed for 13% of patients at the final encounter. Nevertheless, sensitivity analysis using 2 alternate approaches corroborated our low back pain outcomes.

Imperfect placebo treatments are common in low back pain trials.[39] The factorial design limited our ability to assess the sham OMT and sham UST treatments for their independent placebo effects. According to a Cochrane Collaboration review,[6] only 1 trial of spinal manipulation for chronic low back pain has ever evaluated patient blinding.[40] The investigators in that trial reported a mean pain score reduction of 6 mm (16% from baseline) on a visual analog scale, with 6 sham manipulation treatments over 2 weeks, and concluded that blinding was adequate.[40] Similarly, when extrapolated to a 100-mm visual analog scale with a standard deviation of 25 mm,[31] a systematic review of 27 clinical trials reported a standardized mean effect corresponding to a pain reduction of 7 mm with placebo treatments.[19] By comparison, our sham OMT patients achieved a median pain score reduction of 9 mm (20% from baseline) on a visual analog scale, with 6 treatments over 8 weeks. Nevertheless, some degree of unblinding remained possible despite these surrogate data on patient blinding.

In conclusion, the OMT patients achieved moderate to substantial improvements in low back pain, which met or exceeded the Cochrane Back Review Group criterion for a medium effect size. The OMT patients also reported less frequent concurrent use of prescription drugs. They did not, however, report corresponding improvements in back-specific functioning, general health, or work disability. The OMT regimen was safe, parsimonious, and well accepted by patients as demonstrated by high levels of treatment adherence and satisfaction with back care. By contrast, UST was not efficacious in relieving chronic low back pain.

References

1. Licciardone JC. The epidemiology and medical management of low back pain during ambulatory medical care visits in the United States. *Osteopath Med Prim Care*. 2008;2(1):11.

2. Katz JN. Lumbar disc disorders and low-back pain: socioeconomic factors and consequences. *J Bone Joint Surg Am*. 2006;88(Suppl 2): 21-24.

3. Manek NJ, MacGregor AJ. Epidemiology of back disorders: prevalence, risk factors, and prognosis. *Curr Opin Rheumatol*. 2005;17(2): 134-140.

4. Chou R, Qaseem A, Snow V, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians; American College of Physicians; American Pain Society Low Back Pain Guidelines Panel. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. *Ann Intern Med*. 2007;147(7):478-491.

5. National Institute for Health and Clinical Excellence. Developed by the National Collaborating Centre for Primary Care. Low back pain: early management of persistent non-specific low back pain. NICE clinical guideline 88. 2009. http://www.nice.org.uk/nicemedia/ live/11887/44343/44343.pdf.

6. Rubinstein SM, van Middelkoop M, Assendelft WJ, de Boer MR, van Tulder MW. Spinal manipulative therapy for chronic low-back pain: an update of a Cochrane review. *Spine (Phila Pa 1976)*. 2011; 36(13):E825-E846.

7. Cronholm PF, Nicklin DE. Is spinal manipulation an effective treatment for low back pain? No: evidence shows no clinically significant benefit over watchful waiting. *Am Fam Physician*. 2012;85(8):763-764.

8. Hoehler FK, Tobis JS, Buerger AA. Spinal manipulation for low back pain. *JAMA*. 1981;245(18):1835-1838.

9. Gibson T, Grahame R, Harkness J, Woo P, Blagrave P, Hills R. Controlled comparison of short-wave diathermy treatment with osteopathic treatment in non-specific low back pain. *Lancet*. 1985; 1(8440):1258-1261.

10. Cleary C, Fox JP. Menopausal symptoms: an osteopathic investigation. *Complement Ther Med*. 1994;2(4):181-186.

11. Andersson GB, Lucente T, Davis AM, Kappler RE, Lipton JA, Leurgans S. A comparison of osteopathic spinal manipulation with standard care for patients with low back pain. *N Engl J Med*. 1999;341 (19):1426-1431.

12. Burton AK, Tillotson KM, Cleary J. Single-blind randomised controlled trial of chemonucleolysis and manipulation in the treatment of symptomatic lumbar disc herniation. *Eur Spine J*. 2000;9(3):202-207.

13. Licciardone JC, Stoll ST, Fulda KG, et al. Osteopathic manipulative treatment for chronic low back pain: a randomized controlled trial. *Spine (Phila Pa 1976)*. 2003;28(13):1355-1362.

14. Seco J, Kovacs FM, Urrutia G. The efficacy, safety, effectiveness, and cost-effectiveness of ultrasound and shock wave therapies for low back pain: a systematic review. *Spine J*. 2011;11(10):966-977.

15. Licciardone JC, King HH, Hensel KL, Williams DG. OSTEOPAThic Health outcomes In Chronic low back pain: The OSTEOPATHIC Trial. *Osteopath Med Prim Care*. 2008;2:5.

16. Bigos S, Bowyer O, Braen G, et al. Acute low back problems in adults. Clinical Practice Guideline No. 14. Rockville, MD: Agency for Healthcare Research and Quality, Public Health Service, U.S. Department of Health and Human Services; 1994.

17. DeStefano LA. *Greenman's Principles of Manual Medicine*. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.

18. Glossary of osteopathic terminology. In: Ward RC, ed. *Foundations for Osteopathic Medicine*. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:1229-1253.

19. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. *N Engl J Med*. 2001;344(21):1594-1602.

20. Senna MK, Machaly SA. Does maintained spinal manipulation therapy for chronic nonspecific low back pain result in better long-term outcome? *Spine (Phila Pa 1976)*. 2011;36(18):1427-1437.

21. Speed CA. Therapeutic ultrasound in soft tissue lesions. *Rheumatology (Oxford)*. 2001;40(12):1331-1336.

22. Deyle GD, Henderson NE, Matekel RL, Ryder MG, Garber MB, Allison SC. Effectiveness of manual physical therapy and exercise in osteoarthritis of the knee. A randomized, controlled trial. *Ann Intern Med*. 2000;132(3):173-181.

23. Bellg AJ, Borrelli B, Resnick B, et al; Treatment Fidelity Workgroup of the NIH Behavior Change Consortium. Enhancing treatment fidelity in health behavior change studies: best practices and recommendations from the NIH Behavior Change Consortium. *Health Psychol*. 2004;23(5):443-451.

24. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain*. 2008;9(2):105-121.

25. Emshoff R, Bertram S, Emshoff I. Clinically important difference thresholds of the visual analog scale: a conceptual model for identifying meaningful intraindividual changes for pain intensity. *Pain*. 2011;152(10):2277-2282.

26. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. *Pain*. 2000;88(3):287-294.

27. Bombardier C. Outcome assessments in the evaluation of treatment of spinal disorders: summary and general recommendations. *Spine (Phila Pa 1976)*. 2000;25(24):3100-3103.

28. Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. *Spine (Phila Pa 1976)*. 1983;8(2):141-144.

29. Ware JE, Snow KK, Kosinski M, Gandek B. *SF-36 Health Survey: Manual and Interpretation Guide*. Boston, MA: New England Medical Center; 1993.

30. Licciardone JC, Brimhall AK, King LN. Osteopathic manipulative treatment for low back pain: a systematic review and meta-analysis of randomized controlled trials. *BMC Musculoskelet Disord*. 2005;6:43.

31. Assendelft WJ, Morton SC, Yu EI, Suttorp MJ, Shekelle PG. Spinal manipulative therapy for low back pain. A meta-analysis of effectiveness relative to other therapies. *Ann Intern Med*. 2003;138(11): 871-881.

32. Pocock SJ. Current controversies in data monitoring for clinical trials. *Clin Trials*. 2006;3(6):513-521.

33. Furlan AD, Pennick V, Bombardier C, van Tulder M. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. *Spine (Phila Pa 1976)*. 2009;34(18):1929-1941.

34. Hogan MD, Kupper LL, Most BM, Haseman JK. Alternatives to Rothman's approach for assessing synergism (or antagonism) in cohort studies. *Am J Epidemiol*. 1978;108(1):60-67.

35. Hennekens CH, Demets D. The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. *JAMA*. 2009;302(21):2361-2362.

36. Deyo RA, Mirza SK, Turner JA, Martin BI. Overtreating chronic back pain: time to back off? *J Am Board Fam Med*. 2009;22(1):62-68.

37. Harvey E, Burton AK, Moffett JK, Breen A; UK BEAM trial team. Spinal manipulation for low-back pain: a treatment package agreed to by the UK chiropractic, osteopathy and physiotherapy professional associations. *Man Ther*. 2003;8(1):46-51.

38. Dworkin RH, Turk DC, McDermott MP, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. *Pain*. 2009;146(3):238-244.

39. Machado LA, Kamper SJ, Herbert RD, Maher CG, McAuley JH. Imperfect placebos are common in low back pain trials: a systematic review of the literature. *Eur Spine J*. 2008;17(7):889-904.

40. Waagen GN, Haldeman S, Cook G, Lopez D, DeBoer KF. Short term trial of chiropractic adjustments for the relief of chronic low back pain. *Man Med*. 1986;2:63-67.